卖什么
特药依从性技术。
商业模式拆解
买家：谁掌握预算？
未核实Commercial, patient services and field reimbursement leaders at biopharma companies.
触发点：什么让他们现在购买？
Getting patients to start and stay on specialty therapy: manual intake work blocks starts; e.g. Madrigal pairs its newly approved MASH therapy with Courier Health technology.
工作流：什么输入变成什么输出？
Unify patient data across the access ecosystem into one journey view; orchestrate the next action for each patient; AI intake automates manual enrollment work; engagement tools measure outcomes.
经济账：省了什么，怎么收费？
Claimed customer results: over 40% improvement in time to therapy, over 15% increase in patient starts, over 10% uplift in 6-month persistency. Raised a $50M Series B.
渠道：怎么接触到客户？
Enterprise sales ("Contact us"); thought leadership such as the State of Patient-Centricity in Biopharma 2026 report.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-04-23 | — | $50M | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.